Intravitreal fluocinolone acetonide implant (ILUVIEN) for the treatment of retinol conditions. A review of clinical studies.

No Thumbnail Available
Authors
Mushtaq, Y
Mushtaq, M.M
Gatzioufas, Z
Ripa, M
Motta, L
Panos, G.D
Issue Date
2023
Type
Scientific Paper
Language
Keywords
Research Subject Categories::MEDICINE::Physiology and pharmacology::Ophtalmology
Research Projects
Organizational Units
Journal Issue
Alternative Title
Abstract
Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non–infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.
Description
Citation
Mushtaq Y, Mushtaq MM, Gatzioufas Z, Ripa M, Motta L, Panos GD. Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies. Drug Des Devel Ther. 2023 Mar 30;17:961-975. doi: 10.2147/DDDT.S403259. PMID: 37020801; PMCID: PMC10069638.
Publisher
License
Journal
Volume
Issue
PubMed ID
ISSN
EISSN